Preclinical QSP Modeling in the Pharmaceutical Industry: An IQ Consortium Survey Examining the Current Landscape
-
- Marjoleen J.M.A. Nijsen
- Abbvie Inc North Chicago Illinois USA
-
- Fan Wu
- Novartis Institutes for Biomedical Research East Hanover New Jersey USA
-
- Loveleena Bansal
- GlaxoSmithKline King of Prussia Philadelphia USA
-
- Erica Bradshaw‐Pierce
- Takeda San Diego California USA
-
- Jason R. Chan
- Eli Lilly and Company Indianapolis Indiana USA
-
- Bianca M. Liederer
- Genentech Inc. South San Francisco California USA
-
- Jerome T. Mettetal
- AstraZeneca, Drug Safety and Metabolism, IMED Biotech Unit, AstraZeneca Boston Massachusetts USA
-
- Patricia Schroeder
- Biogen Cambridge Massachusetts USA
-
- Edgar Schuck
- Eisai Inc Woodcliff Lake New Jersey USA
-
- Alice Tsai
- Vertex Pharmaceuticals Incorporated Boston Massachusetts USA
-
- Christine Xu
- Sanofi Bridgewater New jersey USA
-
- Anjaneya Chimalakonda
- Bristol‐Myers Squibb Princeton New Jersey USA
-
- Kha Le
- Agios Boston Massachusetts USA
-
- Mark Penney
- UCB Celltech, Slough Berkshire United Kingdom
-
- Brian Topp
- Merck & Co., Inc Kenilworth New Jersey USA
-
- Akihiro Yamada
- Astellas Pharma Inc. Tokyo Japan
-
- Mary E. Spilker
- Pfizer Worldwide Research and Development San Diego California USA
説明
<jats:p>A cross‐industry survey was conducted to assess the landscape of preclinical quantitative systems pharmacology (QSP) modeling within pharmaceutical companies. This article presents the survey results, which provide insights on the current state of preclinical QSP modeling in addition to future opportunities. Our results call attention to the need for an aligned definition and consistent terminology around QSP, yet highlight the broad applicability and benefits preclinical QSP modeling is currently delivering.</jats:p>
収録刊行物
-
- CPT: Pharmacometrics & Systems Pharmacology
-
CPT: Pharmacometrics & Systems Pharmacology 7 (3), 135-146, 2018-02
Wiley
